Little Green Pharma (ASX: LGP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Little Green Pharma Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Little Green Pharma (ASX: LGP)
Latest News
Cannabis Shares
ASX cannabis stocks eyeing $1 billion domestic market
Cannabis Shares
2 ASX cannabis shares with big news today
Cannabis Shares
Could ASX cannabis shares be set for a smoking hot rebound?
Cannabis Shares
Why are these 2 ASX cannabis stocks sputtering today?
Cannabis Shares
Could ASX cannabis shares be set for a resurgence?
Cannabis Shares
Why ASX cannabis shares just jumped back into the spotlight
Cannabis Shares
Little Green Pharma share price shoots 13% higher after capital raise
Cannabis Shares
Why did this ASX cannabis share just rocket 46%?
Cannabis Shares
Why are these 2 ASX cannabis shares booming all of a sudden?
Cannabis Shares
Little Pharma shares lift 8% amid appointment of 'highly regarded' director
Cannabis Shares
Why did the Little Green Pharma share price flame 23% higher today?
Cannabis Shares
ASX cannabis shares in spotlight amid COVID prevention research
LGP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Little Green Pharma
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. Its medicines are cultivated, without pesticides, in a hydroponic facility. The company was founded in 2017 and is headquartered in West Perth, Australia.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 May 2026 | Fleta Solomon | Sell | 8,404 | $790 |
On-market trade.
|
| 26 May 2026 | Fleta Solomon | Sell | 5,000 | $475 |
On-market trade. As per announcement
|
| 26 Feb 2026 | Michael Lynch-Bell | Exercise | 140,000 | $15,400 |
Conversion of securities. 300,000 rights
|
| 26 Feb 2026 | Michael Lynch-Bell | Buy | 140,000 | $15,400 |
Conversion of securities.
|
| 26 Feb 2026 | Neale Fong | Exercise | 70,000 | $7,700 |
Conversion of securities. 150,000 rights
|
| 26 Feb 2026 | Neale Fong | Buy | 70,000 | $7,700 |
Conversion of securities.
|
| 01 Sep 2025 | Angus Caithness | Issued | 2,000,000 | $260,000 |
Issue of options.
|
| 01 Sep 2025 | Fleta Solomon | Issued | 1,200,000 | $156,000 |
Issue of options.
|
| 01 Sep 2025 | Paul Long | Issued | 2,000,000 | $260,000 |
Issue of options.
|
| 15 Jul 2025 | Michael Lynch-Bell | Exercise | 70,000 | $7,350 |
Conversion of securities. 440000 Rights, as per announcement on 22-07-2025
|
| 15 Jul 2025 | Michael Lynch-Bell | Issued | 70,000 | $7,350 |
Conversion of securities.
|
| 15 Jul 2025 | Neale Fong | Exercise | 35,000 | $3,675 |
Conversion of securities. 220000 Rights, as per announcement on 22-07-2025
|
| 15 Jul 2025 | Neale Fong | Issued | 35,000 | $3,675 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Neale William Fong | Non-Executive Director | Nov 2018 |
Dr Fong has 35 years in leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organisations. He is the chairperson of the Risk committee.
|
| Mr Michael David Lynch-Bell | Non-Executive ChairmanNon-Executive Director | Nov 2018 |
Mr Lynch-Bell has experience as corporate finance executive and consultant. Mr Lynch-Bell Ernst & Young career was focused on auditing clients within the oil and gas sectors and later added mining to his portfolio. Mr Lynch-Bell has been involved advising companies on fundraising, reorganisations, transactions, corporate governance as well as IPOs. He is a member of the Risk committee.
|
| Mr Paul Long | Chief Executive OfficerManaging Director | Aug 2023 |
Mr Long has expertise in the global medicinal cannabis sector and the capital markets. Mr Long worked as a consultant in enterprise health, health technology, and retail pharmaceutical sectors. Mr Long was a former Chief Executive Officer of Onsite Health Solutions.
|
| Mr Seth Yakatan | Non-Executive Director | Jun 2026 |
--
|
| Mr Thomas Huppert | Non-Executive Director | Jun 2026 |
--
|
| Mr Brent Dennison | Non-Executive Chairman | Jun 2026 |
--
|
| Mr Alistair Warren | Company Secretary | Jul 2020 |
-
|
| Ms Paula Butler | Chief Financial Officer | Jun 2026 |
-
|
| Paula Butler | Chief Financial Officer |
-
|
|
| Alistair Warren | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| UBS Nominees Pty Ltd | 34,388,475 | 11.24% |
| Thorney International Pty Ltd | 22,690,049 | 7.42% |
| Ms Fleta Jennifer Solomon | 20,723,216 | 6.78% |
| Barbright Australia Pty Ltd <Interquartz> Super <A/C> | 13,732,793 | 4.49% |
| BNP Paribas Nominees Pty Ltd Acf Clearstream | 7,333,346 | 2.40% |
| HSBC Custody Nominees (Australia) Limited | 6,480,007 | 2.12% |
| Mr Angus Caithness | 5,751,441 | 1.88% |
| Banquo Consulting Pty Ltd | 5,413,333 | 1.77% |
| Netwealth Investments Limited <Wrap> Services <A/C> | 5,348,533 | 1.75% |
| CG Nominees (Australia) Pty Ltd | 4,147,061 | 1.36% |
| Two Willows Pty Ltd <Two> Willows Superfund <A/C> | 3,861,000 | 1.26% |
| Citicorp Nominees Pty Limited | 3,430,231 | 1.12% |
| Jasforce Pty Ltd | 2,883,878 | 0.94% |
| Mr Suwandi Broto + Mrs Siew Broto | 2,826,015 | 0.92% |
| Finclear Services Pty Ltd <Superhero> Securities <A/C> | 2,523,287 | 0.82% |
| Mr Paul Frederick Long <The> Long <A/C> | 2,426,191 | 0.79% |
| Ms Jenny Lorraine Mckay <J> & K Mckay Family <A/C> | 2,189,746 | 0.72% |
| H & K Properties Pty Ltd | 2,000,000 | 0.65% |
| Mr Michael David Lynch-Bell | 1,968,450 | 0.64% |
| FSG (Holding) Pty Ltd | 1,916,000 | 0.63% |
